(156 days)
Not Found
No
The device description focuses on the mechanical components and delivery system of a vena cava filter. There is no mention of AI, ML, image processing, or any software-driven analysis or decision-making capabilities.
Yes
The device is indicated for the prevention of recurrent pulmonary embolism and other thromboembolic diseases, which is a therapeutic purpose.
No
This device is a vena cava filter, which is an implantable medical device used to prevent pulmonary embolism by physically capturing blood clots. Its function is interventional/preventative, not diagnostic.
No
The device description clearly outlines physical components like a self-expanding Nitinol filter, a delivery catheter, wireforms, crimps, retrieval tails, tissue anchors, and marker bands. These are all hardware components, not software.
Based on the provided information, the Crux VCF System is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use: The intended use is for the prevention of recurrent pulmonary embolism by physically filtering blood in the inferior vena cava. This is a therapeutic intervention, not a diagnostic test performed on samples outside the body.
- Device Description: The device is a physical filter and delivery system designed to be implanted within the patient's body. IVD devices are typically reagents, instruments, or systems used to examine specimens (like blood, urine, or tissue) in vitro (outside the body) to provide information for diagnosis, monitoring, or screening.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples, using reagents, or providing diagnostic information based on laboratory testing.
Therefore, the Crux VCF System is a medical device, specifically an implantable filter, but it does not fit the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Crux VCF System is indicated for the prevention of recurrent pulmonary embolism via percutaneous placement in the inferior vena cava (IVC) in the following situations:
- Pulmonary thromboembolism when anticoagulants are contraindicated .
- Failure of anticoagulant therapy in thromboembolic diseases .
- Emergency treatment following massive pulmonary embolism where anticipated . benefits of conventional therapy are reduced
- Chronic, recurrent pulmonary embolism where anticoagulant therapy has failed or . is contraindicated
The Crux VCF may be removed according to the instructions contained in the Instructions for Use section "Optional Retrieval of the Crux VCF" in patients who no longer require a vena cava filter. Retrieval of the filter can be performed by femoral or jugular approach.
Product codes (comma separated list FDA assigned to the subject device)
DTK
Device Description
The Crux VCF System is an endovascular medical device used in the prevention of recurrent pulmonary embolism (PE). The system consists of a self-expanding Nitinol filter delivered from a single-use, disposable 9Fr catheter, which can be used percutaneously to deploy the filter. The filter wireforms are composed of two opposing self-expanding Nitinol spiral elements connected at each end with Nitinol crimps. One end of each wireform is formed into a sinusoidal shaped retrieval tail to aid in retrieval of the filter using a snare. Each retrieval tail has an atraumatic plasma ball and a radiopaque tantalum marker band to facilitate visualization. There are five tissue anchors attached to the wireforms elements with Nitinol tubing. The filter is designed to treat IVC diameters of 17 to 28mm.
The delivery catheter for the Crux VCF is a disposable, 9Fr introducer-sheathcompatible, single-use delivery catheter. The filter is provided loaded in the Crux VCF System for jugular or femoral approach delivery. The delivery catheter is an over-thewire system, 0.035" guidewire-compatible, and consists of a polycarbonate inner shaft and a nylon outer shaft. The inner shaft consists of the guidewire lumen and a flexible, radiopaque tracking tip. The outer shaft has a radiopaque distal marker band, a Touhy-Borst hemostasis valve and a one-way checkvalve for flushing.
The filter can be retrieved with commercially available snares and sheaths via either the jugular or femoral approach.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
inferior vena cava (IVC)
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance testing was conducted to establish substantial equivalence to the predicate device as outlined below:
In vitro testing
Biocompatibility
Shipping and Packaging
Dimensional and Visual Inspection
Deployment
Retrievability
Trackability
Deployment Radial Force
Bond and Torque Strength
MRI Compatibility
Clot Trapping
Fatigue
Corrosion
In vivo testing (Pre-clinical)
Deployment
Retrieval
Positional Stability
IVC histopathology
Clinical Testing Summary:
A clinical trial was conducted under an approved IDE and IRB protocol to further establish the safety, effectiveness and substantial equivalence to the predicate device. One hundred and twenty-five (125) subjects with a temporary or permanent risk of recurrent pulmonary embolism were enrolled into a prospective, single arm, multinational clinical trial. Subjects were followed for 180 days or 30 days after filter retrieval. The primary endpoint of clinical success is defined as technical success of deployment and freedom from PE, filter migration, and device related adverse events requiring intervention. Secondary endpoints include retrieval success, filter migration, IVCF thrombosis, and device integrity.
The technical success rate was 123/125 (98%). There were 3 cases of recurrent PE (2.4%) and no cases of embolization, migration or fracture. There were 8 cases of asymptomatic, new inferior vena cava (IVC) thrombus including 5 observed at retrieval evaluation. Clinical Success was 96% (91.8% lower one-sided 95% CL exceeding the 80). Retrieval success was 53/54 (98%) at a mean of 83 ± 57 days (range 7 to 190) with 1 radiographic anomaly observed with no clinical sequelae.
The clinical trial demonstrated the safe deployment, implant and retrieval of the filter. Technical and retrieval success are high, with a low rate of device related complications.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Technical success rate was 123/125 (98%).
3 cases of recurrent PE (2.4%).
Clinical Success was 96% (91.8% lower one-sided 95% CL exceeding the 80).
Retrieval success was 53/54 (98%).
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.3375 Cardiovascular intravascular filter.
(a)
Identification. A cardiovascular intravascular filter is an implant that is placed in the inferior vena cava for the purpose of preventing pulmonary thromboemboli (blood clots generated in the lower limbs and broken loose into the blood stream) from flowing into the right side of the heart and the pulmonary circulation.(b)
Classification. Class II. The special controls for this device are:(1) “Use of International Standards Organization's ISO 10993 ‘Biological Evaluation of Medical Devices Part I: Evaluation and Testing,’ ” and
(2) FDA's:
(i) “510(k) Sterility Review Guidance and Revision of 2/12/90 (K90-1)” and
(ii) “Guidance for Cardiovascular Intravascular Filter 510(k) Submissions.”
0
K120402
510(k) Summary Crux Vena Cava Filter System 21 CFR 807.92
JUL 1 3 2012 1
| Device Common Name: | Vena Cava Filter |
|---|---|
| Applicant / Manufacturer: | Crux Biomedical, Inc. |
| 1455 Adams Drive, #1170 | |
| Menlo Park, CA USA 94025 | |
| Tel: 650-321-9903 | |
| Fax: 650-321-9904 | |
| Correspondent Contact | |
| Information: | Elisa Hebb |
| Vice President, Clinical and Regulatory Affairs | |
| Crux Biomedical, Inc. | |
| 1455 Adams Drive, #1170 | |
| Menlo Park, CA 94025 | |
| Tel: 650-321-9903 | |
| Fax: 650-321-9904 | |
| Email: ehebb@cruxbiomedical.com | |
| Device Classification | |
| Regulation & Name: | 21 CFR 870.3375, Cardiovascular intravascular filter |
| Device Classification & | |
| Product Codes: | Class II, DTK |
| Panel: | Cardiovascular |
| Prior FDA Document | |
| Numbers: | G070035/S001 through G070035/S032 |
| Device Proprietary Name: | Crux Vena Cava Filter System |
| Basis of Submission: | New Device |
| Kit Description: | Crux Vena Cava Filter System consists of: |
| • Crux Vena Cava Filter | |
| • Crux Delivery Catheter | |
| Number of Devices in | |
| Submission | • 7014 – Crux Vena Cava Filter System - Femoral |
| • 7015 – Crux Vena Cava Filter System - Jugular |
Intended Use
The Crux VCF System is indicated for the prevention of recurrent pulmonary embolism via percutaneous placement in the inferior vena cava (IVC) in the following situations:
- Pulmonary thromboembolism when anticoagulants are contraindicated .
- Failure of anticoagulant therapy in thromboembolic diseases .
1
- Emergency treatment following massive pulmonary embolism where anticipated . benefits of conventional therapy are reduced
- Chronic, recurrent pulmonary embolism where anticoagulant therapy has failed or . is contraindicated
The Crux VCF may be removed according to the instructions contained in the Instructions for Use section "Optional Retrieval of the Crux VCF" in patients who no longer require a vena cava filter. Retrieval of the filter can be performed by femoral or jugular approach.
Device Description - Crux Vena Cava Filter (VCF) System
The Crux VCF System is an endovascular medical device used in the prevention of recurrent pulmonary embolism (PE). The system consists of a self-expanding Nitinol filter delivered from a single-use, disposable 9Fr catheter, which can be used percutaneously to deploy the filter. The filter wireforms are composed of two opposing self-expanding Nitinol spiral elements connected at each end with Nitinol crimps. One end of each wireform is formed into a sinusoidal shaped retrieval tail to aid in retrieval of the filter using a snare. Each retrieval tail has an atraumatic plasma ball and a radiopaque tantalum marker band to facilitate visualization. There are five tissue anchors attached to the wireforms elements with Nitinol tubing. The filter is designed to treat IVC diameters of 17 to 28mm.
The delivery catheter for the Crux VCF is a disposable, 9Fr introducer-sheathcompatible, single-use delivery catheter. The filter is provided loaded in the Crux VCF System for jugular or femoral approach delivery. The delivery catheter is an over-thewire system, 0.035" guidewire-compatible, and consists of a polycarbonate inner shaft and a nylon outer shaft. The inner shaft consists of the guidewire lumen and a flexible, radiopaque tracking tip. The outer shaft has a radiopaque distal marker band, a Touhy-Borst hemostasis valve and a one-way checkvalve for flushing.
The filter can be retrieved with commercially available snares and sheaths via either the jugular or femoral approach.
Predicate Device Information
| Predicate Device: | Option Vena Cava Filter |
|---|---|
| 510(k) Numbers: | K081410 |
2
| Device Manufacturer: | Rex Medical
100 East Hector St. Suite 245
Conshocken, PA 19428 |
|-----------------------------------|----------------------------------------------------------------------|
| Device Common Name: | Cardiovascular Filter |
| Device Classification
Name: | 21 CFR 870.3375, Cardiovascular intravascular
filters |
| Device Classification &
Codes: | Class II, DTK |
Comparison to Predicate Device
Both the Crux VCF System and predicate device share similar designs, mode of operation and materials. Both filters are delivered to the vena cava via transcatheter approach. When deployed, the nitinol material utilized in both the predicate and subject devices allows for self-centering of the filter. Both filters are designed with anchors to secure the filter to vessel wall and both filters can be safely retrieved via catheterization.
The primary differences between the predicate and subject devices are the filter geometry and the addition of ePTFE filter web incorporated in the Crux VCF design. Based on the design verification and validation results, the variation in geometry and addition of the ePTFE filter web do not have an adverse impact on the safety and effectiveness of the VCF when compared to the predicate device.
As demonstrated in the results of the clinical trial, these differences in design do not adversely affect the clinical outcomes when compared to the predicate device and the devices are substantially equivalent.
Other areas of substantial equivalence with predicate device: Intended Use Indications for Use Target Patient Population Mode of Operations
Summary of Supporting Data
Performance testing was conducted to establish substantial equivalence to the predicate device as outlined below:
In vitro testing Biocompatibility Shipping and Packaging
3
Dimensional and Visual Inspection Deployment Retrievability Trackability Deployment Radial Force Bond and Torque Strength MRI Compatibility Clot Trapping Fatigue Corrosion
In vivo testing (Pre-clinical) Deployment Retrieval Positional Stability IVC histopathology
Clinical Testing Summary:
A clinical trial was conducted under an approved IDE and IRB protocol to further establish the safety, effectiveness and substantial equivalence to the predicate device. One hundred and twenty-five (125) subjects with a temporary or permanent risk of recurrent pulmonary embolism were enrolled into a prospective, single arm, multinational clinical trial. Subjects were followed for 180 days or 30 days after filter retrieval. The primary endpoint of clinical success is defined as technical success of deployment and freedom from PE, filter migration, and device related adverse events requiring intervention. Secondary endpoints include retrieval success, filter migration, IVCF thrombosis, and device integrity.
The technical success rate was 123/125 (98%). There were 3 cases of recurrent PE (2.4%) and no cases of embolization, migration or fracture. There were 8 cases of asymptomatic, new inferior vena cava (IVC) thrombus including 5 observed at retrieval evaluation. Clinical Success was 96% (91.8% lower one-sided 95% CL exceeding the 80). Retrieval success was 53/54 (98%) at a mean of 83 ± 57 days (range 7 to 190) with 1 radiographic anomaly observed with no clinical sequelae.
4
The clinical trial demonstrated the safe deployment, implant and retrieval of the filter. Technical and retrieval success are high, with a low rate of device related complications.
Conclusion:
Bench test, animal test and the clinical trial results demonstrate that the device meets the established success criteria and is substantially equivalent to the predicate device.
5
Image /page/5/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized symbol that resembles a caduceus, which is a traditional symbol of medicine. The symbol is composed of three abstract shapes that suggest a staff with two snakes coiled around it.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
Crux Biomedical, Inc. c/o Ms. Elisa Hebb Vice President, Clinical and Regulatory Affairs 1455 Adams Drive, # 1170 Menlo Park, CA 94025
Re: K120402
Trade/Device Name: Crux Vena Cava Filter System Regulation Number: 21 CFR 870.3375 Regulation Name: Cardiovascular intravascular filter Regulatory Class: Class II Product Code: DTK Dated: July 9, 2012 Received: July 10, 2012
Dear Ms. Hebb:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. · Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21
JUL 1 3 2012
6
Page 2 - Ms. Hebb
CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical Or FC r ar bo 7) a created (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 1000 97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
M. G. Killeen
Gram Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
7
Indications for Use Statement
510(k) Number: This application
Crux Vena Cava Filter System Device Name:
Indications For Use:
The Crux VCF System is indicated for the prevention of recurrent pulmonary embolism via percutaneous placement in the inferior vena cava (IVC) in the following situations:
- Pulmonary thromboembolism when anticoagulants are contraindicated .
- . Failure of anticoagulant therapy in thromboembolic diseases
- . Emergency treatment following massive pulmonary embolism where anticipated benefits of conventional therapy are reduced
- Chronic, recurrent pulmonary embolism where anticoagulant therapy has failed or . is contraindicated
The Crux VCF may be removed according to the instructions contained in the section "Optional Retrieval of the Crux VCF" in patients who no longer require a vena cava filter. Retrieval of the filter can be performed by femoral or jugular approach.
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
Page 1 of
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
W.G. Helleh
(Division Sign-Off) Division of Cardiovascular Devices
510(k) Number K120402
K120402 RFI 23Mar2012 Crux Biomedical, Inc.
Page 488 of 581